Loading...
XNAS
AMRN
Market cap166mUSD
Apr 04, Last price  
0.40USD
1D
-4.73%
1Q
-23.81%
Jan 2017
-86.93%
Name

Amarin Corporation PLC

Chart & Performance

D1W1MN
P/E
—
P/S
0.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.71%
Rev. gr., 5y
-13.79%
Revenues
205m
-33.34%
500,000500,0007,365,0000000026,351,00054,202,00081,756,000130,084,000181,104,000229,214,000429,755,000614,060,000583,187,000369,193,000306,911,000204,590,000
Net income
-82m
L+39.03%
-18,707,000-26,920,000-38,197,000-20,021,000-59,317,000-249,589,000-69,126,000-179,184,000-166,227,000-56,364,000-115,204,000-86,350,000-67,865,000-116,445,000-22,645,000-18,000,0007,729,000-105,803,000-59,112,000-82,183,000
CFO
-31m
L
-17,306,000-22,909,000-26,279,000-26,392,000-28,112,000-33,870,000-39,439,000-122,303,000-190,336,000-72,309,000-84,748,000-71,815,000-32,837,000-94,703,000-9,366,000-21,746,000-66,537,000-180,092,0006,880,000-31,020,000
Earnings
Apr 18, 2025

Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
URL
https://amarincorp.com/
IPO date
Apr 01, 1993
Employees
365
Domiciled in
IE
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
204,590
-33.34%
306,911
-16.87%
369,193
-36.69%
Cost of revenue
296,387
363,527
461,536
Unusual Expense (Income)
NOPBT
(91,797)
(56,616)
(92,343)
NOPBT Margin
Operating Taxes
(4,983)
5,442
1,998
Tax Rate
NOPAT
(86,814)
(62,058)
(94,341)
Net income
(82,183)
39.03%
(59,112)
-44.13%
(105,803)
-1,468.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
239
(379)
BB yield
-0.07%
0.08%
Debt
Debt current
10,034
Long-term debt
15,446
17,474
20,030
Deferred revenue
2,509
13,147
Other long-term liabilities
11,501
9,064
8,205
Net debt
(278,774)
(303,185)
(280,572)
Cash flow
Cash from operating activities
(31,020)
6,880
(180,092)
CAPEX
(599)
Cash from investing activities
(46)
(25,522)
175,288
Cash from financing activities
(1)
230
(379)
FCF
(62,183)
(75,810)
32,535
Balance
Cash
294,220
320,659
309,361
Long term investments
1,275
Excess cash
283,990
305,313
292,176
Stockholders' equity
(1,363,248)
(1,283,607)
(1,228,249)
Invested Capital
1,868,648
1,856,014
1,864,983
ROIC
ROCE
EV
Common stock shares outstanding
410,937
407,655
401,155
Price
0.49
-44.25%
0.87
-28.10%
1.21
-64.09%
Market cap
199,304
-43.80%
354,660
-26.93%
485,398
-64.21%
EV
(79,470)
51,475
204,826
EBITDA
(88,784)
(53,651)
(89,247)
EV/EBITDA
0.90
Interest
7
8
15
Interest/NOPBT